alexa Pioglitazone: A Better Choice of Drug in the Pre-diabet
ISSN: 2155-6156

Journal of Diabetes & Metabolism
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Pioglitazone: A Better Choice of Drug in the Pre-diabetic Patients with High Risk of Cardiovascular Diseases

Manan B Dave*

Shri Sarvajanik Pharmacy College, Near Arvind Baug, Mehsana, Gujarat, India

*Corresponding Author:
Manan B Dave
Shri Sarvajanik Pharmacy College
Near Arvind Baug, Mehsana
Gujarat, India
Tel: +918733068549
E-mail: [email protected]

Received date: August 26, 2014; Accepted date: September 27, 2014; Published date: October 06, 2014

Citation: Dave MB (2014) Pioglitazone: A Better Choice of Drug in the Pre-diabetic Patients with High Risk of Cardiovascular Diseases. J Diabetes Metab 5:447. doi: 10.4172/2155-6156.1000447

Copyright: © 2014 Dave MB, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Prediabetes is an intermediate condition between normal glycemia and clinical diabetes. Person with prediabetes condition have more chances of occurring diabetes and its associated cardiovascular disorder. Intervention of prediabetic person reduces its progression to diabetes and other cardiovascular diseases. Pioglitazone, a thiazolidinedione insulin sensitizer acts on peroxisome proliferator activated receptor and have a good response in diabetic condition. Apart from glycemic benefits it has anti-atherogenicity action that prevents the progression of cardiovascular disorder. These emerging effects of the drug pioglitazone on atherosclerosis warrant a better place in the management of diabetic patients with high risk of coronary artery disease.

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords